Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.

NCT Number	NCT07649525
Lead Sponsor	University of Leeds Collaborators: Cancer Research UK, Blood Cancer UK, Johnson & Johnson
Conditions	Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
Enrollment	1,226 participants
Start Date	2026-07
Primary Completion	2033-06 (estimated)
Study Completion	2037-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-15